Cargando…

O1.6. INCREASED COMPLEMENT FACTORS C3 AND C4 IN SCHIZOPHRENIA AND THE EARLY STAGES OF PSYCHOSIS: IMPLICATIONS FOR CLINICAL SYMPTOMATOLOGY AND CORTICAL THICKNESS

BACKGROUND: The complement system - a key component of the innate immune system, has been proposed to contribute to the pathogenesis of schizophrenia. Recently, complement C4 was associated with increased risk of schizophrenia, and in a mouse model, developmentally-timed synaptic pruning. These obse...

Descripción completa

Detalles Bibliográficos
Autores principales: Cropley, Vanessa, Laskaris, Liliana, Zalesky, Andrew, Weickert, Cynthia Shannon, Biase, Maria Di, Chana, Gursharan, Baune, Bernhard, Bousman, Chad, Nelson, Barnaby, McGorry, Patrick D, Everall, Ian, Pantelis, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888408/
http://dx.doi.org/10.1093/schbul/sby015.188
_version_ 1783312515243966464
author Cropley, Vanessa
Laskaris, Liliana
Zalesky, Andrew
Weickert, Cynthia Shannon
Biase, Maria Di
Chana, Gursharan
Baune, Bernhard
Bousman, Chad
Nelson, Barnaby
McGorry, Patrick D
Everall, Ian
Pantelis, Christos
author_facet Cropley, Vanessa
Laskaris, Liliana
Zalesky, Andrew
Weickert, Cynthia Shannon
Biase, Maria Di
Chana, Gursharan
Baune, Bernhard
Bousman, Chad
Nelson, Barnaby
McGorry, Patrick D
Everall, Ian
Pantelis, Christos
author_sort Cropley, Vanessa
collection PubMed
description BACKGROUND: The complement system - a key component of the innate immune system, has been proposed to contribute to the pathogenesis of schizophrenia. Recently, complement C4 was associated with increased risk of schizophrenia, and in a mouse model, developmentally-timed synaptic pruning. These observations have led to proposals that abnormal activation of the complement system might contribute to the development of schizophrenia by disrupting synaptic pruning during key developmental periods. However, despite renewed interest in the complement system in schizophrenia it remains unclear whether peripheral complement levels differ in cases compared to controls, change over the course of illness and whether they are associated with current symptomatology and brain cortical thickness. This study aimed to: i) investigate whether peripheral complement protein levels are altered at different stages of illness, and ii) identify patterns among complement protein levels that predict clinical symptoms and grey matter thickness across the cortex. METHODS: Complement factors C1q, C3 and C4 were quantified in 183 participants [n=83 Healthy Controls (HC), n=10 Ultra-High Risk (UHR) for psychosis, n=40 First Episode Psychosis (FEP), n=50 Chronic schizophrenia] using Multiplex ELISA. Permutation-based t-tests were used to assess between-group differences in complement protein levels at each of the three illness stages, relative to age- and gender-matched healthy controls. Canonical correlation analysis was used to identify patterns of complement protein levels that correlated with clinical symptoms and regional thickness across the cortex. RESULTS: C3 and C4 were significantly increased in FEP and UHR patients, whereas only C4 was significantly increased in chronic patients. A molecular pattern of increased C4 and decreased C3 was associated with positive and negative symptom severity in the pooled patient sample. Increased C4 levels alone, or decreased C3 levels alone, did not correlate with symptom severity as strongly as the pattern of increased C4 in combination with decreased C3. Preliminary canonical correlation analyses revealed that, in healthy controls, a molecular pattern characterised by increased C3 and decreased C4 was associated with relatively thinner paracentral, inferior parietal and inferior temporal cortices, but relatively thicker insular, in the left hemisphere. In the pooled patient group, a trend for increased C3 in combination with decreased C1q was associated with relatively thinner left lateral occipital cortex and pars orbitalis but relatively thicker pars opercularis and precuneus. DISCUSSION: Our findings indicate that peripheral complement concentration is particularly increased early and preceding psychosis and its imbalance may be associated with symptom severity and variation in regional grey matter thickness across the cortex.
format Online
Article
Text
id pubmed-5888408
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-58884082018-04-11 O1.6. INCREASED COMPLEMENT FACTORS C3 AND C4 IN SCHIZOPHRENIA AND THE EARLY STAGES OF PSYCHOSIS: IMPLICATIONS FOR CLINICAL SYMPTOMATOLOGY AND CORTICAL THICKNESS Cropley, Vanessa Laskaris, Liliana Zalesky, Andrew Weickert, Cynthia Shannon Biase, Maria Di Chana, Gursharan Baune, Bernhard Bousman, Chad Nelson, Barnaby McGorry, Patrick D Everall, Ian Pantelis, Christos Schizophr Bull Abstracts BACKGROUND: The complement system - a key component of the innate immune system, has been proposed to contribute to the pathogenesis of schizophrenia. Recently, complement C4 was associated with increased risk of schizophrenia, and in a mouse model, developmentally-timed synaptic pruning. These observations have led to proposals that abnormal activation of the complement system might contribute to the development of schizophrenia by disrupting synaptic pruning during key developmental periods. However, despite renewed interest in the complement system in schizophrenia it remains unclear whether peripheral complement levels differ in cases compared to controls, change over the course of illness and whether they are associated with current symptomatology and brain cortical thickness. This study aimed to: i) investigate whether peripheral complement protein levels are altered at different stages of illness, and ii) identify patterns among complement protein levels that predict clinical symptoms and grey matter thickness across the cortex. METHODS: Complement factors C1q, C3 and C4 were quantified in 183 participants [n=83 Healthy Controls (HC), n=10 Ultra-High Risk (UHR) for psychosis, n=40 First Episode Psychosis (FEP), n=50 Chronic schizophrenia] using Multiplex ELISA. Permutation-based t-tests were used to assess between-group differences in complement protein levels at each of the three illness stages, relative to age- and gender-matched healthy controls. Canonical correlation analysis was used to identify patterns of complement protein levels that correlated with clinical symptoms and regional thickness across the cortex. RESULTS: C3 and C4 were significantly increased in FEP and UHR patients, whereas only C4 was significantly increased in chronic patients. A molecular pattern of increased C4 and decreased C3 was associated with positive and negative symptom severity in the pooled patient sample. Increased C4 levels alone, or decreased C3 levels alone, did not correlate with symptom severity as strongly as the pattern of increased C4 in combination with decreased C3. Preliminary canonical correlation analyses revealed that, in healthy controls, a molecular pattern characterised by increased C3 and decreased C4 was associated with relatively thinner paracentral, inferior parietal and inferior temporal cortices, but relatively thicker insular, in the left hemisphere. In the pooled patient group, a trend for increased C3 in combination with decreased C1q was associated with relatively thinner left lateral occipital cortex and pars orbitalis but relatively thicker pars opercularis and precuneus. DISCUSSION: Our findings indicate that peripheral complement concentration is particularly increased early and preceding psychosis and its imbalance may be associated with symptom severity and variation in regional grey matter thickness across the cortex. Oxford University Press 2018-04 2018-04-01 /pmc/articles/PMC5888408/ http://dx.doi.org/10.1093/schbul/sby015.188 Text en © Maryland Psychiatric Research Center 2018. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Cropley, Vanessa
Laskaris, Liliana
Zalesky, Andrew
Weickert, Cynthia Shannon
Biase, Maria Di
Chana, Gursharan
Baune, Bernhard
Bousman, Chad
Nelson, Barnaby
McGorry, Patrick D
Everall, Ian
Pantelis, Christos
O1.6. INCREASED COMPLEMENT FACTORS C3 AND C4 IN SCHIZOPHRENIA AND THE EARLY STAGES OF PSYCHOSIS: IMPLICATIONS FOR CLINICAL SYMPTOMATOLOGY AND CORTICAL THICKNESS
title O1.6. INCREASED COMPLEMENT FACTORS C3 AND C4 IN SCHIZOPHRENIA AND THE EARLY STAGES OF PSYCHOSIS: IMPLICATIONS FOR CLINICAL SYMPTOMATOLOGY AND CORTICAL THICKNESS
title_full O1.6. INCREASED COMPLEMENT FACTORS C3 AND C4 IN SCHIZOPHRENIA AND THE EARLY STAGES OF PSYCHOSIS: IMPLICATIONS FOR CLINICAL SYMPTOMATOLOGY AND CORTICAL THICKNESS
title_fullStr O1.6. INCREASED COMPLEMENT FACTORS C3 AND C4 IN SCHIZOPHRENIA AND THE EARLY STAGES OF PSYCHOSIS: IMPLICATIONS FOR CLINICAL SYMPTOMATOLOGY AND CORTICAL THICKNESS
title_full_unstemmed O1.6. INCREASED COMPLEMENT FACTORS C3 AND C4 IN SCHIZOPHRENIA AND THE EARLY STAGES OF PSYCHOSIS: IMPLICATIONS FOR CLINICAL SYMPTOMATOLOGY AND CORTICAL THICKNESS
title_short O1.6. INCREASED COMPLEMENT FACTORS C3 AND C4 IN SCHIZOPHRENIA AND THE EARLY STAGES OF PSYCHOSIS: IMPLICATIONS FOR CLINICAL SYMPTOMATOLOGY AND CORTICAL THICKNESS
title_sort o1.6. increased complement factors c3 and c4 in schizophrenia and the early stages of psychosis: implications for clinical symptomatology and cortical thickness
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888408/
http://dx.doi.org/10.1093/schbul/sby015.188
work_keys_str_mv AT cropleyvanessa o16increasedcomplementfactorsc3andc4inschizophreniaandtheearlystagesofpsychosisimplicationsforclinicalsymptomatologyandcorticalthickness
AT laskarisliliana o16increasedcomplementfactorsc3andc4inschizophreniaandtheearlystagesofpsychosisimplicationsforclinicalsymptomatologyandcorticalthickness
AT zaleskyandrew o16increasedcomplementfactorsc3andc4inschizophreniaandtheearlystagesofpsychosisimplicationsforclinicalsymptomatologyandcorticalthickness
AT weickertcynthiashannon o16increasedcomplementfactorsc3andc4inschizophreniaandtheearlystagesofpsychosisimplicationsforclinicalsymptomatologyandcorticalthickness
AT biasemariadi o16increasedcomplementfactorsc3andc4inschizophreniaandtheearlystagesofpsychosisimplicationsforclinicalsymptomatologyandcorticalthickness
AT chanagursharan o16increasedcomplementfactorsc3andc4inschizophreniaandtheearlystagesofpsychosisimplicationsforclinicalsymptomatologyandcorticalthickness
AT baunebernhard o16increasedcomplementfactorsc3andc4inschizophreniaandtheearlystagesofpsychosisimplicationsforclinicalsymptomatologyandcorticalthickness
AT bousmanchad o16increasedcomplementfactorsc3andc4inschizophreniaandtheearlystagesofpsychosisimplicationsforclinicalsymptomatologyandcorticalthickness
AT nelsonbarnaby o16increasedcomplementfactorsc3andc4inschizophreniaandtheearlystagesofpsychosisimplicationsforclinicalsymptomatologyandcorticalthickness
AT mcgorrypatrickd o16increasedcomplementfactorsc3andc4inschizophreniaandtheearlystagesofpsychosisimplicationsforclinicalsymptomatologyandcorticalthickness
AT everallian o16increasedcomplementfactorsc3andc4inschizophreniaandtheearlystagesofpsychosisimplicationsforclinicalsymptomatologyandcorticalthickness
AT pantelischristos o16increasedcomplementfactorsc3andc4inschizophreniaandtheearlystagesofpsychosisimplicationsforclinicalsymptomatologyandcorticalthickness